Duality Biotherapeutics Announces EGM Poll Results: Key Resolutions Passed
Duality Biotherapeutics Announces EGM Poll Results: Key Resolutions Passed
Hong Kong, April 29, 2026 — Duality Biotherapeutics, Inc. (Stock Code: 9606), a biopharmaceutical company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, has released the official poll results from its Extraordinary General Meeting (EGM) held on April 29, 2026. All proposed resolutions, including several that may have significant implications for the company’s future operations and share value, were approved by shareholders.
Key Highlights for Investors
-
Unanimous Support for Major Strategic Moves: All 12 resolutions received strong shareholder backing, with most ordinary resolutions passing with more than 99% of votes in favor.
-
Approval of RMB Share Issue: The most significant item was the approval of the RMB Share Issue and the associated Specific Mandate, which authorizes the company to issue new shares denominated in Renminbi (RMB) and list them on the Shanghai Stock Exchange’s Sci-Tech Board.
-
Governance and Operational Changes: New rules of procedure for shareholder and board meetings were adopted, effective upon the RMB share listing. Amendments to the Articles of Association were also approved as a special resolution.
-
Price Stabilization and Dividend Plans: Shareholders approved a three-year price stabilization plan and a dividend return plan post-RMB Share Issue, both of which could directly influence future returns and share price stability.
-
Other Resolutions: These include plans for managing accumulated unrecovered losses, use of proceeds from the RMB Share Issue, and remedial measures for dilution of immediate returns.
Detailed Breakdown of Passed Resolutions
| Resolution |
For |
Against |
Key Details |
| RMB Share Issue and Specific Mandate |
46,784,003 (99.32%) |
320,220 (0.68%) |
Approval to issue RMB-denominated shares and list on Sci-Tech Board. |
| Authorization to Board for RMB Share Issue |
46,765,455 (99.28%) |
338,768 (0.72%) |
Board and authorized persons can manage all matters related to the RMB Share Issue. |
| Plan for Accumulated Unrecovered Losses |
46,784,003 (99.32%) |
320,220 (0.68%) |
Approach to handle losses prior to RMB Share Issue. |
| Price Stabilization Plan (3 Years) |
46,784,003 (99.32%) |
320,220 (0.68%) |
Strategies to support RMB Share price post-listing. |
| Dividend Return Plan (3 Years) |
47,045,823 (99.88%) |
58,400 (0.12%) |
Ensures dividend distribution policy for RMB Shares. |
| Use of Proceeds from RMB Share Issue |
46,784,003 (99.32%) |
320,220 (0.68%) |
Details on application of funds raised. |
| Remedial Measures for Immediate Return Dilution |
46,784,003 (99.32%) |
320,220 (0.68%) |
Actions to mitigate potential EPS dilution. |
| Undertakings and Binding Measures |
46,784,003 (99.32%) |
320,220 (0.68%) |
Formal commitments regarding RMB Share Issue. |
| Rules of Procedures for Shareholders’ Meetings |
47,104,223 (100%) |
0 (0%) |
New procedural rules for meetings, effective with RMB listing. |
| Rules of Procedures for Board Meetings |
47,104,223 (100%) |
0 (0%) |
Updated board meeting practices, effective with RMB listing. |
| Authorization to Directors/Senior Management |
46,795,055 (99.34%) |
309,168 (0.66%) |
Empowers management to execute all necessary actions and documentation. |
| Special Resolution: Amendments to Articles of Association |
45,447,410 (96.48%) |
1,656,813 (3.52%) |
Adoption of updated Articles with effect from RMB Share listing. |
Important Information for Shareholders
-
Shareholder Participation: As of the EGM date, the company had 90,419,414 issued shares. All shares were eligible to vote, and there were no shares requiring abstention or special voting rights. No shareholder indicated an intention to vote against or abstain from any resolution.
-
Scrutineer and Board Attendance: The Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as scrutineer. All directors participated in the EGM, either in person or electronically.
-
Next Steps: The adoption and implementation of these resolutions, especially the RMB Share Issue and associated governance and operational changes, may have a direct impact on the company’s market value, liquidity, and investor sentiment in both Hong Kong and the prospective Sci-Tech Board listing in mainland China.
Potential Impact on Share Value
The successful passage of the RMB Share Issue and related strategic resolutions paves the way for Duality Biotherapeutics to access mainland capital markets, diversify its investor base, and enhance its financial flexibility. The proposed price stabilization and dividend return plans are particularly noteworthy as they may support the share price post-listing and provide confidence to both existing and new investors.
Amendments to the Articles of Association and new meeting procedures reflect a significant step in aligning corporate governance with best practices and regulatory requirements for dual-listed companies. These actions, alongside the detailed use-of-proceeds plan and remedial measures for potential dilution, demonstrate management’s commitment to shareholder value and transparency.
Board Composition
- Executive Directors: Dr. Zhu Zhongyuan (Chairman & CEO), Mr. Zhang Shaoren, Dr. Hua Haiqing
- Non-Executive Directors: Mr. Cai Zhiyang, Dr. Yu Tao
- Independent Non-Executive Directors: Mr. Xie Dong, Mr. Gao Fengyong, Ms. Chuai Shuyin
Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice or an offer to buy or sell any securities. Investors should review the official company circular and consult financial advisors before making investment decisions. The author is not responsible for any losses arising from reliance on this article.
View DUALITYBIO-B Historical chart here
